Table 6.
Recommendations on use of venous thromboembolism (VTE) prophylaxis
| Guideline | VTE prophylaxis recommendations | Notes |
|---|---|---|
| World Health Organization9 | Use pharmacological prophylaxis (low molecular weight heparin (preferred if available) or heparin 5000 units subcutaneously twice daily) in adolescents and adults without contraindications. For those with contraindications, use mechanical prophylaxis (intermittent pneumatic compression devices) | No clear link to supportive evidence. Some indication that recommendations are based on previously published guidelines |
| Ministry of Health, Brazil10 | Use pharmacological prophylaxis in patients without contraindications. If there are contraindications, use mechanical prophylaxis | Based on WHO guidelines |
| National Health Commission, China25 | No specific advice given | |
| COREB mission nationale, France11 | No specific advice given | |
| Robert Koch Institute, Germany12 | No specific advice given | |
| Ministry of Health, Holland26 | No specific advice given | |
| Ministry of Health and Family Welfare, India14 | Use pharmacological prophylaxis (low molecular weight heparin (preferred if available) or heparin 5000 units subcutaneously twice daily) in adolescents and adults without contraindications. For those with contraindications, use mechanical prophylaxis (intermittent pneumatic compression devices) | No clear link to supportive evidence. Some indication that recommendations are based on previously published guidelines |
| Ministry of Health, Indonesia13 | Use prophylactic drugs (low molecular weight heparin if available, or 5000 subcutaneous heparin units twice a day) in adolescent and adult patients when no contraindications. If there are contraindications use mechanical prophylaxis | No clear link to supportive evidence |
| Società Italiana di Malattie Infettive e Tropicali, Italy15 | No specific advice given | |
| Japanese Association of Infectious Diseases, Japan16 | No specific advice given | |
| Department of Public Health, Malaysia17 | No specific advice given | |
| Working group on COVID 2019, Russia18 | No specific advice given | |
| Centre for Disease Control, Saudi Arabia19 | No specific advice given | |
| Central COVID Task Force, South Korea20 | No specific advice given | |
| Ministry of Health, Spain21 | Efforts will be made to avoid the complications listed—pulmonary thromboembolism: prophylactic anticoagulation | No clear link to supportive evidence |
| Center for Disease Control, Taiwan22 | No specific advice given | |
| Ministry of Health, Turkey23 | No specific advice given | |
| Centers for Disease Control and Prevention, USA24 | No specific advice given |